Genetic aberrations in glioblastoma including EGFR, PDGFRA, PIK3CA, PTEN, TP53 and CDKN2A/B etc., drive the dysfunction of signaling pathways such as PI3K/Akt/mTOR, p53 and RB1 pathways, and open up possible therapies for GBM by targeting these pathways with selective inhibitors [4]. This evidence concerns the gene PIK3CA and glioblastoma.